Cardiac Remodeling and Ejection Fraction Dynamics

Cardiac remodelling encompasses the structural and functional alterations that the myocardium undergoes in response to injury, pressure overload or neurohormonal activation. These changes include cellular hypertrophy, extracellular matrix deposition and chamber dilatation, which together influence systolic performance as measured by left ventricular ejection fraction (LVEF). A declining ejection fraction reflects impaired contractile function and portends progression to symptomatic heart failure, whereas reverse remodelling—characterised by regression of pathological geometry and restoration of function—often accompanies clinical improvement. Understanding the dynamic interplay between remodelling and ejection fraction is crucial for risk stratification, the development of imaging biomarkers and the optimisation of therapies designed to halt or reverse maladaptive processes. Recent advances in molecular biology, imaging technologies and pharmacotherapy have deepened insight into the mechanisms driving remodelling and have emphasised the need for personalised approaches that preserve or recover ventricular function.

Research from Nature Portfolio

A prespecified analysis of a large trial investigating patients whose LVEF had improved beyond 40 per cent demonstrated that adding a sodium–glucose cotransporter 2 inhibitor to existing guideline-directed medical therapy reduced the combined risk of cardiovascular death or worsening heart failure. Importantly, the magnitude of benefit in patients with recovered ejection fraction was comparable to that seen in individuals with an EF consistently above 40 per cent. These findings extend the indication for modern heart failure therapies to patients in whom reverse remodelling has already occurred, underscoring that sustained medical treatment remains critical despite apparent functional recovery.

Research from all publishers

Innovations in deep learning have yielded a transformer-based platform capable of analysing dual-stained histological images to predict both heart failure risk and the potential for left ventricular reverse remodelling. By segmenting cellular nuclei and quantifying morphological and DNA-damage markers, this approach achieved over 90 per cent accuracy in identifying patients likely to recover systolic function, paving the way for image-guided personalised management.

A landmark open-label trial of therapy withdrawal in patients with recovered dilated cardiomyopathy revealed that nearly half of those whose medications were phased out experienced relapse within six months, with recurrent dilatation, falling ejection fraction and rising natriuretic peptide levels. Even among patients who initially maintained stability, tissue-level and functional deterioration emerged over time. This work highlights the absence of reliable predictors of sustained recovery and supports the indefinite continuation of heart failure treatment until robust markers of stability are defined.

A comprehensive systematic review and meta-analysis encompassing over 9,000 individuals estimated that approximately 22 per cent of patients with reduced ejection fraction progress to an improved-EF phenotype under current therapies. This subgroup exhibited a roughly 56 per cent reduction in all-cause mortality and lower rates of heart failure-related hospitalisation, emphasising the prognostic and epidemiological importance of reverse remodelling across diverse clinical settings.

Cardiac Remodeling and Ejection Fraction Dynamics publication trend

The graph below shows the total number of articles in cardiac remodeling and ejection fraction dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Cardiac remodelling: Structural and functional adaptation of the heart muscle in response to stress or injury, involving changes in chamber dimensions, wall thickness and extracellular matrix composition.

Ejection fraction: The percentage of blood expelled from the left ventricle with each heartbeat, serving as a key measure of systolic performance.

Left ventricular reverse remodelling: The process by which pathological alterations in left ventricular geometry and function regress, often accompanying therapeutic benefit and improved outcomes.

Heart failure with improved ejection fraction (HFimpEF): A clinical subset in which patients initially present with reduced ejection fraction and subsequently demonstrate a sustained rise above a defined threshold, reflecting partial or complete functional recovery.

References

1. TRAITER: transformer-guided diagnosis and prognosis of heart failure using cell nuclear morphology and DNA damage marker. Bioinformatics (2024).
2. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. The Lancet (2018).
3. Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine (2021).
4. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine (2022).